Saxenda is an anti-obesity drug developed by Novo Nordisk, a Danish pharmaceutical company. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by stimulating the release of insulin and suppressing appetite. Saxenda is administered as a once-daily subcutaneous injection and is approved for use in adults with a body mass index (BMI) of 30 or greater, or those with a BMI of 27 or greater and at least one weight-related comorbidity. It is also approved for use in combination with a reduced-calorie diet and increased physical activity. Saxenda is one of several anti-obesity drugs available on the market. Other drugs include phentermine, liraglutide, orlistat, and bupropion. Companies that produce these drugs include Novo Nordisk, Arena Pharmaceuticals, GlaxoSmithKline, and Orexigen Therapeutics. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
